Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.58)
# 228
Out of 5,241 analysts
52
Total ratings
56.86%
Success rate
35.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintains: Buy | $28 → $50 | $38.97 | +28.30% | 3 | May 15, 2026 | |
| IMNM Immunome | Reiterates: Buy | $40 | $20.88 | +91.57% | 2 | May 13, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $58 → $65 | $49.35 | +31.71% | 4 | May 8, 2026 | |
| ENGN enGene Therapeutics | Maintains: Buy | $25 → $6 | $1.72 | +248.84% | 4 | May 8, 2026 | |
| VSTM Verastem | Reiterates: Buy | $18 | $4.32 | +316.67% | 2 | Apr 10, 2026 | |
| NBP NovaBridge Biosciences | Reiterates: Buy | $9 | $1.82 | +394.51% | 3 | Apr 8, 2026 | |
| CGON CG Oncology | Maintains: Buy | $80 → $100 | $66.93 | +49.41% | 6 | Apr 7, 2026 | |
| AURA Aura Biosciences | Reiterates: Buy | $22 | $7.74 | +184.24% | 2 | Mar 30, 2026 | |
| ERAS Erasca | Maintains: Buy | $15 → $20 | $10.23 | +95.50% | 3 | Mar 13, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $3.79 | +243.01% | 1 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $7.97 | +88.21% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.10 | +350.98% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.52 | +676.55% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.00 | +600.00% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $20.23 | +97.73% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $11.03 | +262.65% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $8.77 | +162.26% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $59.27 | +77.16% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $10.50 | +90.48% | 1 | Aug 8, 2025 |
Sutro Biopharma
May 15, 2026
Maintains: Buy
Price Target: $28 → $50
Current: $38.97
Upside: +28.30%
Immunome
May 13, 2026
Reiterates: Buy
Price Target: $40
Current: $20.88
Upside: +91.57%
Scholar Rock Holding
May 8, 2026
Maintains: Buy
Price Target: $58 → $65
Current: $49.35
Upside: +31.71%
enGene Therapeutics
May 8, 2026
Maintains: Buy
Price Target: $25 → $6
Current: $1.72
Upside: +248.84%
Verastem
Apr 10, 2026
Reiterates: Buy
Price Target: $18
Current: $4.32
Upside: +316.67%
NovaBridge Biosciences
Apr 8, 2026
Reiterates: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
CG Oncology
Apr 7, 2026
Maintains: Buy
Price Target: $80 → $100
Current: $66.93
Upside: +49.41%
Aura Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $22
Current: $7.74
Upside: +184.24%
Erasca
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $10.23
Upside: +95.50%
Foghorn Therapeutics
Mar 10, 2026
Reiterates: Buy
Price Target: $13
Current: $3.79
Upside: +243.01%
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $7.97
Upside: +88.21%
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.10
Upside: +350.98%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.52
Upside: +676.55%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.00
Upside: +600.00%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $20.23
Upside: +97.73%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $11.03
Upside: +262.65%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $8.77
Upside: +162.26%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $59.27
Upside: +77.16%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $10.50
Upside: +90.48%